JP2024508347A5 - - Google Patents

Info

Publication number
JP2024508347A5
JP2024508347A5 JP2023537357A JP2023537357A JP2024508347A5 JP 2024508347 A5 JP2024508347 A5 JP 2024508347A5 JP 2023537357 A JP2023537357 A JP 2023537357A JP 2023537357 A JP2023537357 A JP 2023537357A JP 2024508347 A5 JP2024508347 A5 JP 2024508347A5
Authority
JP
Japan
Prior art keywords
optionally substituted
sulfur
nitrogen
oxygen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/064339 external-priority patent/WO2022140252A1/en
Publication of JP2024508347A publication Critical patent/JP2024508347A/ja
Publication of JP2024508347A5 publication Critical patent/JP2024508347A5/ja
Pending legal-status Critical Current

Links

JP2023537357A 2020-12-21 2021-12-20 エステル結合アセタールを含むナノ材料 Pending JP2024508347A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063128680P 2020-12-21 2020-12-21
US63/128,680 2020-12-21
US202163223971P 2021-07-20 2021-07-20
US63/223,971 2021-07-20
US202163287390P 2021-12-08 2021-12-08
US63/287,390 2021-12-08
PCT/US2021/064339 WO2022140252A1 (en) 2020-12-21 2021-12-20 Nanomaterials comprising ester-linked acetals

Publications (2)

Publication Number Publication Date
JP2024508347A JP2024508347A (ja) 2024-02-27
JP2024508347A5 true JP2024508347A5 (cg-RX-API-DMAC10.html) 2024-12-27

Family

ID=82159839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537357A Pending JP2024508347A (ja) 2020-12-21 2021-12-20 エステル結合アセタールを含むナノ材料

Country Status (9)

Country Link
US (1) US20230331657A1 (cg-RX-API-DMAC10.html)
EP (1) EP4262819A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024508347A (cg-RX-API-DMAC10.html)
KR (1) KR20230133986A (cg-RX-API-DMAC10.html)
AU (1) AU2021410666A1 (cg-RX-API-DMAC10.html)
CA (1) CA3203295A1 (cg-RX-API-DMAC10.html)
IL (1) IL303365A (cg-RX-API-DMAC10.html)
MX (1) MX2023007137A (cg-RX-API-DMAC10.html)
WO (1) WO2022140252A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600208B2 (ja) 2019-07-29 2024-12-16 ジョージア テック リサーチ コーポレイション 拘束された脂質を含むナノ材料およびその使用
CN115175894B (zh) 2020-01-09 2024-09-06 盖德治疗有限责任公司 纳米材料
EP4262817A4 (en) * 2020-12-21 2025-03-12 Beam Therapeutics Inc. NANOMATERIALS WITH ACETALS
CN116761888A (zh) 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料
EP4281080A4 (en) 2021-01-20 2025-09-24 Beam Therapeutics Inc NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
US20230263742A1 (en) * 2021-05-06 2023-08-24 Stemirna Therapeutics Co., Ltd. A lipid
WO2023044343A1 (en) * 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023121965A1 (en) * 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterial comprising diamines
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023138611A1 (en) * 2022-01-19 2023-07-27 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
EP4540222A1 (en) 2022-07-20 2025-04-23 Beam Therapeutics Inc. Nanomaterials comprising triols
JP2025540623A (ja) 2022-11-11 2025-12-16 ビーム セラピューティクス インク. トランスサイレチン遺伝子の塩基編集
WO2024112775A1 (en) * 2022-11-25 2024-05-30 Beam Therapeutics Inc. Compositions and methods for editing a transthyretin gene
CN120418427A (zh) 2022-12-23 2025-08-01 因特利亚治疗公司 用于基因组编辑的系统和方法
CN118108613B (zh) * 2022-12-26 2025-05-06 北京新合睿恩生物医疗科技有限公司 一种阳离子脂质化合物及制备方法和应用、mRNA递送系统
WO2024192291A1 (en) * 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025000542A1 (en) * 2023-06-30 2025-01-02 Shanghai Vitalgen Biopharma Co., Ltd. Ionizable cationic lipid compounds for delivery of biologically active agents
TW202517607A (zh) * 2023-07-19 2025-05-01 香港商正基基因科技有限公司 脂質和脂質奈米顆粒
EP4762030A1 (en) * 2023-08-16 2026-06-24 Beam Therapeutics Inc. Ionizable lipids with branched head groups
WO2025159966A1 (en) * 2024-01-23 2025-07-31 Beam Therapeutics Inc. Compositions and methods for altering a nucleobase in a transthyretin polynucleotide
WO2025212851A2 (en) 2024-04-03 2025-10-09 Orbital Therapeutics, Inc. mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES
WO2025259931A1 (en) 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization
WO2026006203A2 (en) 2024-06-24 2026-01-02 Orbital Therapeutics, Inc. Compositions and methods for making circular rna
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026006687A1 (en) 2024-06-28 2026-01-02 Orbital Therapeutics, Inc. Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus
WO2026096539A1 (en) 2024-10-28 2026-05-07 Beam Therapeutics Inc. Secondary alcohol lipids
WO2026126136A1 (en) * 2024-12-11 2026-06-18 Helex Inc. Novel acetal oxolane lipids

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2075970B (en) * 1980-04-10 1984-05-02 Nippon Paint Co Ltd Polymerisable amino acid compounds and their production
EP1021549A2 (en) 1997-09-19 2000-07-26 Sequitur, Inc. SENSE mRNA THERAPY
DE19940641A1 (de) * 1999-08-26 2001-03-01 Basf Ag Verfahren zur Herstellung von 4-Acyl-aminosäureestern und N-Acyl-Aminoacetalen
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
MX2019009070A (es) * 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
MX2021003455A (es) * 2018-10-02 2021-09-21 Intellia Therapeutics Inc Lípidos con amina ionizables.
WO2020219876A1 (en) * 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
CN115175894B (zh) * 2020-01-09 2024-09-06 盖德治疗有限责任公司 纳米材料
AU2021269137A1 (en) * 2020-05-08 2022-12-15 Orna Therapeutics, Inc. Circular RNA compositions and methods

Similar Documents

Publication Publication Date Title
JP2024503976A5 (cg-RX-API-DMAC10.html)
TWI789695B (zh) 治療sars cov-2感染之方法
JP2024505449A5 (cg-RX-API-DMAC10.html)
JP2025501731A5 (cg-RX-API-DMAC10.html)
JP2024503441A5 (cg-RX-API-DMAC10.html)
TWI715944B (zh) 治療性化合物
JP2024502948A5 (cg-RX-API-DMAC10.html)
JP2024542755A5 (cg-RX-API-DMAC10.html)
TWI878811B (zh) 用於治療病毒感染的化合物及方法
KR20220164784A (ko) 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
JP2024542541A5 (cg-RX-API-DMAC10.html)
JP2024502954A5 (cg-RX-API-DMAC10.html)
TW202400185A (zh) 用於治療病毒感染的化合物及方法
WO2017190145A1 (en) Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
JP2021102643A5 (cg-RX-API-DMAC10.html)
JP7832717B2 (ja) 硫化物を含むイオン化可能な脂質、及びこれを含む脂質ナノ粒子
JP2018138570A (ja) 癌の治療のためのamg900の使用
WO2025146125A1 (zh) 用于递送的脂质化合物和脂质纳米颗粒
CN117430541A (zh) 用于向细胞递送的化合物及其组合物
CN102058574A (zh) 富马酸衍生物在治疗心功能不全中的应用
KR20250164231A (ko) 작용제의 전달을 위한 지질 나노입자
EP4346772B1 (en) Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
JP6469727B2 (ja) 線維症の抑制又は治療方法
JP2003527414A (ja) C型肝炎を治療するための薬剤
WO2024220742A9 (en) Conjugated polyethyleneimine compounds and compositions, and uses thereof for the treatment of atherosclerosis, cardiovascular, and lung disease